Astellas Announces Completion of Acquisition of Own Shares, and Cancellation of Treasury Stock

On March 10, 2022 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported the status and the completion of acquisition of its own shares based on the resolution of the Board of Directors’ meeting held on February 2, 2022, pursuant to the Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act (Press release, Astellas, MAR 10, 2022, View Source [SID1234609839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also announced the number of shares to be canceled on March 29, 2022 pursuant to Article 178 of the Companies Act has been finalized.

Particulars

Status of acquisition of own shares
(1) Class of shares acquired: Common stock of the Company
(2) Total number of shares acquired: 11,096,700 shares
(3) Total amount of acquisition cost: 20,642,021,200 yen
(4) Period of acquisition: From March 1, 2022 to March 9, 2022
(5) Method of acquisition: Purchased on the Tokyo Stock Exchange

Details of the cancellation of treasury stock
(1) Class of shares to be cancelled: Common stock of the Company
(2) Number of shares to be cancelled: 25,935,500 shares
(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.40%)
(3) Cancellation date: March 29, 2022

(Reference)

Details of the resolution at the meeting of the Board of Directors on February 2, 2022
(1) Class of shares to be acquired: Common stock of the Company
(2) Total number of shares to be acquired: Up to 29 million shares
(Ratio to the total number of shares outstanding [excluding treasury stock): 1.57%]
(3) Total amount of acquisition cost: Up to 50 billion yen
(4) Period of acquisition: From February 3, 2022 to March 24, 2022

Accumulated Company’s own shares acquired pursuant to the above board resolution
(1) Total number of shares acquired: 25,935,500 shares
(2) Total amount of acquisition cost: 49,999,849,800 yen
(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.40%)

Details of the decided cancellation of treasury stock (February 2, 2022)
(1) Class of shares to be cancelled: Common stock of the Company
(2) Total number of shares to be cancelled: All of the shares repurchased as stated in 2 above
(3) Scheduled cancellation date: March 29, 2022

Status of shares after cancellation
(1) Number of shares issued: 1,835,851,575 shares (expected)
(2) Number of the Company’s treasury stock: 8,845,998 shares (expected)
[Estimated numbers of shares described above (1) and (2) were calculated on the basis of the issued shares and the Company’s treasury stock as of February 28, 2022, respectively.]